Table 2.
Changes in HAQ scores by therapy and response period
| Mean change in HAQ score (SD) per half-yearly period | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Period | ABA | ADA | BAR | CTZ | ETN | RTX | TCZ | TOF | |
| Short term (first 6 months of treatment) | csDMARD-IR population | − 0.790 (0.408) [24] | − 0.637 (0.350) [25] | − 0.564a (0.512) [25] | − 0.764 (0.390) [25] | − 0.377 (0.486) [25] | − 0.813 (0.379) [25] | − 0.562 (0.351) [25] | − 0.564 (0.512) [25] |
| TNFi-IR population | − 0.360 | − 0.409 | − 0.447a | − 0.350 | − 0.393 | − 0.407 | − 0.437 | − 0.447 | |
| Medium term (6–36 months of treatment) | − 0.050 (0.25b) [27] | − 0.030 (0.25b) [28] | − 0.016 (0.00573a) | − 0.05 (0.25b) | 0 (0.25b) [29] | − 0.010 (0.25b) [31] | − 0.0126 (0.25b) [33] | − 0.016 (0.00573) [32] | |
| Long term (> 36 months of treatment) | 0 (0.15b) | 0 (0.15b) | 0 (0.15b) | 0 (0.15b) | 0 (0.15b) | 0 (0.15b) | 0 (0.15b) | 0 (0.15b) | |
| Safety [36] | |||||||||
| SAE proportion per 6 months | 1.509% | 2.489% | 1.499%a | 3.724% | 2.010% | 1.843% | 2.688% | 1.499% | |
aAssumption. Equivalence to tofacitinib, bassumption for SD
ABA, abatacept; ADA, adalimumab; BAR, baricitinib; CTZ, certolizumab; csDMARD-IR, patients with an inadequate response or intolerance to previous therapy with a disease-modifying antirheumatic drug; ETN, etanercept; HAQ, Health Assessment Questionnaire; RTX, rituximab; SD, standard deviation; TCZ, tocilizumab; TNFi-IR, patients with an inadequate response or intolerance to previous therapy with a tumour necrosis factor inhibitor; TOF, tofacitinib